Sales of Avita Medical's [AVH] respiratory products, including the Funhaler, increased 35 per cent last financial year, making up for the shelving of its CellSpray range of epithelial autograft products.

In a sales update released to the market, Avita said it had appointed pharmacy sales brokers Clear Sales as distributor of the Funhaler, an asthma device for children, for the Australian market earlier this year and is now actively searching for a US distributor following FDA approval last year.

Avita has also appointed a new senior sales executive, John Geisel, as senior vice-president of business development. He has over 35 years experience in medical sales and marketing.

Avita is the result of a merger between Clinical Cell Culture, which contributed the regenerative medicine product line, and Visiomed, an asthma device specialist with an eye on the ophthalmic market.